Neurogene Inc (NGNE)
36.40
+1.58
(+4.54%)
USD |
NASDAQ |
Jun 28, 16:00
36.40
0.00 (0.00%)
After-Hours: 20:00
Neurogene Cash from Financing (Quarterly): -6.524M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -6.524M |
December 31, 2023 | 94.30M |
September 30, 2023 | -1.836M |
Date | Value |
---|---|
June 30, 2023 | -0.086M |
March 31, 2023 | 0.107M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.524M
Minimum
Mar 2024
94.30M
Maximum
Dec 2023
17.19M
Average
-0.086M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
Taysha Gene Therapies Inc | -0.022M |
CEL-SCI Corp | 6.596M |
AIM ImmunoTech Inc | 2.829M |
IGC Pharma Inc | 0.667M |
NovaBay Pharmaceuticals Inc | -0.597M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -21.65M |
Cash from Investing (Quarterly) | 29.94M |
Free Cash Flow | -59.87M |
Free Cash Flow Per Share (Quarterly) | -1.285 |
Free Cash Flow Yield | -30.85% |